tiprankstipranks
Biocryst Pharmaceuticals (DE:BO1)
FRANKFURT:BO1

BioCryst (BO1) Financial Statements

1 Followers

BioCryst Financial Overview

BioCryst's market cap is currently ―. The company's EPS TTM is €; its P/E ratio is ―; BioCryst is scheduled to report earnings on May 2, 2024, and the estimated EPS forecast is €-0.19. See an overview of income statement, balance sheet, and cash flow financials.
Dec 23Sep 23Jun 23Mar 23Dec 22
Income Statement-
Total Revenue$ 93.40M$ 86.74M$ 82.49M-$ 79.55M
Gross Profit$ 91.84M$ 85.64M$ 81.65M$ -938.00K$ 77.05M
EBIT$ -38.58M$ -8.47M$ -45.67M$ -25.27M$ -45.01M
EBITDA$ -107.89M$ 11.70M$ -24.38M$ -6.03M$ -44.61M
Net Income Common Stockholders$ -50.62M$ -40.26M$ -75.33M$ -53.33M$ -71.54M
Balance Sheet-
Cash, Cash Equivalents and Short-Term Investments$ 388.99M$ 397.59M$ 412.24M$ 399.62M$ 424.31M
Total Assets$ 516.96M$ 522.92M$ 529.88M$ 509.74M$ 550.00M
Total Debt$ 317.11M$ 310.24M$ 301.51M$ 240.95M$ 741.45M
Net Debt$ -71.87M$ -87.35M$ -110.73M$ -158.67M$ 317.14M
Total Liabilities$ 972.49M$ 933.91M$ 918.60M$ 838.02M$ 844.60M
Stockholders Equity$ -455.53M$ -410.99M$ -388.71M$ -328.29M$ -294.60M
Cash Flow-
Free Cash Flow$ -9.47M$ -20.88M$ -19.28M$ -47.67M$ -24.38M
Operating Cash Flow$ -8.92M$ -19.90M$ -18.81M$ -47.51M$ -23.85M
Investing Cash Flow$ -28.47M$ 23.12M$ -19.04M$ -107.11M$ 77.22M
Financing Cash Flow$ -3.17M$ 1.23M$ 29.36M$ 5.08M$ 4.20M
Currency in USD

BioCryst Earnings and Revenue History

BioCryst Debt to Assets

BioCryst Cash Flow

BioCryst Forecast EPS vs Actual EPS

What's Included in PREMIUM?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis